Neuronetics prices $30 million stock offering to pay down debt
The NeuroStar TMS maker sold 18.75 million shares at $1.60, partly to meet a loan amendment it says would resolve its going-concern risk.
Neuronetics, maker of the NeuroStar TMS system for depression, said on November 10 that it had priced an underwritten public offering of 18.75 million shares at $1.60 each, for gross proceeds of about $30 million. Underwriters have a 30-day option to buy up to 2,812,500 more shares, and the deal was expected to close around November 12. William Blair is lead bookrunner.
Part of the money will repay a term loan from Perceptive. A November 5 loan amendment lowers some revenue covenants if the company prepays at least $15 million by November 30, and Neuronetics says this would resolve the going-concern risk in its recent filings. The low share price points to tight finances, despite a new accelerated TMS clearance.
Learn more: Transcranial magnetic stimulation · Neuronetics